"Human Skin Cancers: Pathways, Mechanisms, Targets and Treatments" ed. by Miroslav Blumenberg

This volume is dedicated to Human skin cancers - the most common type of tumors, represent a significant health burden.

The deadliest is unquestionably melanoma. Half of melanomas have an activating mutation in the BRAF gene, prompting development of novel drugs, vemurafenib and dabrafenib, specifically targeting mutated BRAF. Trametinib and cobimetinib, which block MEK, a BRAF effector protein, have been used in combination with BRAF inhibitors. A promising new melanoma treatment is immunotherapy, approach that boosts patient's own immune system to attack cancer. Pembrolizumab and nivolumab inhibit PD-1, whereas Ipilimumab targets CTLA-4, another immunity check point, to boost the immune response. Here we focus on pathways, mechanisms, targets and treatments of human skin cancers, with particular emphasis on the new developments in the research on melanomas.



Contents
1 Epigenetics in Melanoma Development and Drug Resistance
2 LncRNAs as Biomarkers for Melanoma
3 The Multiple Roles of Tyrosinase-Related Protein-2/L-Dopachrome Tautomerase in Melanoma: Biomarker, Therapeutic Target, and Molecular Driver in Tumor Progression
4 The Modern Approach to Targeting Melanoma
5 Possibilities for the Therapy of Melanoma: Current Knowledge and Future Directions
6 Squamous Cell Carcinoma: Biomarkers and Potential Therapeutic Targets
7 Correlation between Porcine and Human Skin Models by Optical Methods
8 Molecular Mechanisms and Biomarkers of Skin Photocarcinogenesis